P-219: Relationship between corneal exam findings, best-corrected visual acuity, and ocular symptoms in patients with relapsed or refractory multiple myeloma receiving belantamab mafodotin

Background Belantamab mafodotin (belamaf; GSK2857916) is a B-cell maturation antigen (BCMA)-targeting antibody–drug conjugate approved in the United States and European Union as a monotherapy for heavily pretreated adult patients with relapsed or refractory multiple myeloma (RRMM). Ocular events (OEs) during the pivotal DREAMM-2 trial (NCT03525678) included corneal exam findings (superficial punctate keratopathy and/or microcyst-like epithelial...